Methods for enhancing antibody-induced cell lysis and treating cancer

• US 7,534,772 B2
• Filed: 06/22/2001
• Issued: 05/19/2009
• Est. Priority Date: 06/22/2000
• Status: Expired due to Fees

• Current Assignee: Coley Pharmaceutical GmbH (Pfizer Inc.), University of Iowa Research Foundation
• Original Assignee: Coley Pharmaceutical GmbH (Pfizer Inc.), University of Iowa Research Foundation
• Inventors: Hartmann, Gunther, Weiner, George
• Primary Examiner(s): ANGELL, JON E
• Application Number:
  US09/888,326
• Publication Number:
  US 20030026801A1
• Time in Patent Office: 2,888 Days
• Field of Search: 514/44, 536/24.5, 536/24.3, 536/23.1, 424/130.1, 424/1.11
• US Class Current: 514/44.00R
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/2803 against the immunoglobulin superfamily
• CPC Class Codes: C07K 16/2878 against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
• CPC Class Codes: C07K 16/2896 against molecules with a "CD"-designation, not provided for elsewhere

Abstract

The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.

Claims

1. A method for treating a subject having a B-cell malignancy resistant to therapy with an antibody specific for a surface antigen selected from CD19, CD20, and CD22, wherein cells of the malignancy have low or no baseline expression of the surface antigen, the method comprising:

administering to the subject the immunostimulatory CpG oligonucleotide ODN 2006 (SEQ ID NO;

729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of the surface antigen by the cells; and

administering to the subject an antibody specific for the upregulated surface antigen, in an effective amount to treat the subject.

2. A method for treating a subject having a B-cell malignancy, wherein cells of the B-cell malignancy have low or no baseline expression of CD20, the method comprising:

administering to the subject the immunostimulatory CpG oligonucleotide ODN 2006 (SEQ ID NO;

729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of CD20 by the cells; and

administering to the subject an antibody specific for CD20, in an effective amount to treat the subject.

3. A method for treating a subject having a marginal zone lymphoma or B-cell chronic lymphocytic leukemia, wherein cells of the lymphoma or leukemia have low or no baseline expression of an antigen selected from CD19 and CD22, the method comprising:

administering to the subject the immunostimulatory CpG oligonucleotide ODN 2006 (SEQ ID NO;

729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of the antigen by the cells of the lymphoma or leukemia; and

administering to the subject an antibody specific for the upregulated antigen, in an effective amount to treat the subject.

4. A method for treating a subject having a B-cell malignancy, wherein cells of the malignancy upregulate expression of a surface antigen selected from CD19, CD20, and CD22, in response to immunostimulatory CpG oligonucleotide, the method comprising:

isolating malignant B cells from the subject;

identifying a surface antigen selected from CD19, CD20, and CD22, the expression of which can be upregulated in response to immunostimulatory CpG oligonucleotide, wherein the surface antigen is expressed by the malignant B cells in an amount lower than that of normal B cells;

administering to the subject the immunostimulatory CpG oligonucleotide ODN 2006 (SEQ ID NO;

729) comprising a backbone modification and an unmethylated C, in an effective amount to upregulate expression of the surface antigen by the cells; and

administering to the subject an antibody specific for the upregulated surface antigen, in an amount effective to treat the subject.